Quest Diagnostics launches novel blood test for myeloma with advanced flow cytometry.

Quest Diagnostics has launched a novel blood test called Quest Flow Cytometry MRD for Myeloma, which uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with myeloma. The test provides comparable sensitivity as next-generation sequencing methods at a fraction of the cost, supporting better care and outcomes. The test is as sensitive as next-generation sequencing methods and has five-day specimen stability to support nationwide testing.